Tony Liu, CBMG CEO
A newly private Novartis partner bags a megaround on its first go to turbocharge CAR-T, cell therapy pipeline
An early forerunner of Chinese biotech’s growing influence globally, Cellular Biomedicine — or CBMG – appeared to be taking two steps backward when it delisted on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
